|
1
|
Assi H, Missenard G, Terrier P, et al:
Intensive induction chemotherapy without methotrexate in adult
patients with localized osteosarcoma: results of the Institut
Gustave-Roussy phase II trial. Curr Oncol. 17:23–31. 2010.
|
|
2
|
Yu Y, Luk F, Yang JL and Walsh WR:
Ras/Raf/MEK/ERK pathway is associated with lung metastasis of
osteosarcoma in an orthotopic mouse model. Anticancer Res.
31:1147–1152. 2011.
|
|
3
|
Fisher JL, Mackie PS, Howard ML, et al:
The expression of the urokinase plasminogen activator system in
metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer
Res. 7:1654–1660. 2001.
|
|
4
|
Hingorani P, Zhang W, Gorlick R and Kolb
EA: Inhibition of Src phosphorylation alters metastatic potential
of osteosarcoma in vitro but not in vivo. Clin Cancer Res.
15:3416–3422. 2009.
|
|
5
|
Sueyoshi T, Jono H, Shinriki S, et al:
Therapeutic approaches targeting midkine suppress tumor growth and
lung metastasis in osteosarcoma. Cancer Lett. 316:23–30. 2012.
|
|
6
|
Janeway KA and Walkley CR: Modeling human
osteosarcoma in the mouse: From bedside to bench. Bone. 47:859–865.
2010.
|
|
7
|
Sandberg AA and Bridge JA: Updates on the
cytogenetics and molecular genetics of bone and soft tissue tumors:
osteosarcoma and related tumors. Cancer Genet Cytogenet. 145:1–30.
2003.
|
|
8
|
Meyers PA, Schwartz CL, Krailo M, et al:
Osteosarcoma: a randomized, prospective trial of the addition of
ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and
high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005.
|
|
9
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006.
|
|
10
|
Duffy MJ, O’Donovan N, Brennan DJ, et al:
Survivin: a promising tumor biomarker. Cancer Lett. 249:49–60.
2007.
|
|
11
|
Ryan BM, O’Donovan N and Duffy MJ:
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009.
|
|
12
|
Johnson ME and Howerth EW: Survivin: a
bifunctional inhibitor of apoptosis protein. Vet Pathol.
41:599–607. 2004.
|
|
13
|
Zou J, Gan M, Mao N, et al: Sensitization
of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating
survivin. Arch Med Res. 41:162–169. 2010.
|
|
14
|
Breen EC: VEGF in biological control. J
Cell Biochem. 102:1358–1367. 2007.
|
|
15
|
Saharinen P, Eklund L, Pulkki K, et al:
VEGF and angiopoietin signaling in tumor angiogenesis and
metastasis. Trends Mol Med. 17:347–362. 2011.
|
|
16
|
Lin F, Zheng SE, Shen Z, et al:
Relationships between levels of CXCR4 and VEGF and blood-borne
metastasis and survival in patients with osteosarcoma. Med Oncol.
28:649–653. 2011.
|
|
17
|
Bajpai J, Sharma M, Sreenivas V, et al:
VEGF expression as a prognostic marker in osteosarcoma. Pediatr
Blood Cancer. 53:1035–1039. 2009.
|
|
18
|
Berlin O, Samid D, Donthineni-Rao R, et
al: Development of a novel spontaneous metastasis model of human
osteosarcoma transplanted orthotopically into bone of athymic mice.
Cancer Res. 53:4890–4895. 1993.
|
|
19
|
Thompson PA and Chintagumpala M: Targeted
therapy in bone and soft tissue sarcoma in children and
adolescents. Curr Oncol Rep. 14:197–205. 2012.
|
|
20
|
Zou J, Gan M, Mao N, et al: Sensitization
of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating
survivin. Arch Med Res. 41:162–169. 2010.
|
|
21
|
Wu YF, Liang XJ, Liu YY, et al: +Antisense
oligonucleotide targeting survivin inhibits growth by inducing
apoptosis in human osteosarcoma cells MG-63. Neoplasma. 57:501–506.
2010.
|
|
22
|
Kanwar JR, Kamalapuram SK and Kanwar RK:
Targeting survivin in cancer: patent review. Expert Opin Ther Pat.
20:1723–1737. 2010.
|
